Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Second-line RAS-mutant Advanced Colorectal Cancer
NCT07213570Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in colorectal cancer (CRC), sponsored by National Cancer Institute. Started Oct 2025; status: recruiting.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07213570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213570.